No Data
Express News | Adial Pharmaceuticals FY 2024 GAAP EPS $(2.72) Beats $(2.97) Estimate
10-K: Annual report
Adial Pharmaceuticals Expects Cash to Fund Operations Into 2H of 2025
Adial Pharma Believes Existing Cash and Cash Equivalents Will Fund Oper Expenses Into 2H
Express News | Adial Pharmaceuticals FY Net Income USD -13.2 Million
Adial Pharmaceuticals Shares Are Trading Higher After the Company Announced It Received FDA Feedback for Its Vitro Bridging Strategy of AD04 and Will Proceed to Manufacture Clinical Supplies for Its Upcoming Phase 3 Clinical Trial.
